Last reviewed · How we verify
ovarian cancer peptide vaccine
ovarian cancer peptide vaccine is a Biologic drug developed by University of Virginia. It is currently in Phase 1 development.
At a glance
| Generic name | ovarian cancer peptide vaccine |
|---|---|
| Sponsor | University of Virginia |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- DERMATOLOGY/SKIN:: Injection site reaction/extravasation changes*3
- Nausea
- Injection site reaction
- Fatigue
- METABOLIC/LABORATORY:: Albumin, serum-low (hypoalbuminemia)*3
- BLOOD/BONE MARROW:: Hemoglobin*3
- CONSTITUTIONAL SYMPTOMS:: Fatigue (asthenia, lethargy, malaise)*3
- CONSTITUTIONAL SYMPTOMS:: Rigors/chills*3
- PAIN:: Pain:: Head/headache*3
- PAIN:: Pain:: Muscle*3
- Abdominal pain
- Vomiting
Key clinical trials
- A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients (PHASE2)
- Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (EARLY_PHASE1)
- Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer (PHASE1, PHASE2)
- A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (PHASE1)
- NeoVax With Nivolumab in Patients With Ovarian Cancer (PHASE1)
- Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer (PHASE1)
- PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma (PHASE1, PHASE2)
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ovarian cancer peptide vaccine CI brief — competitive landscape report
- ovarian cancer peptide vaccine updates RSS · CI watch RSS
- University of Virginia portfolio CI
Frequently asked questions about ovarian cancer peptide vaccine
What is ovarian cancer peptide vaccine?
ovarian cancer peptide vaccine is a Biologic drug developed by University of Virginia.
Who makes ovarian cancer peptide vaccine?
ovarian cancer peptide vaccine is developed by University of Virginia (see full University of Virginia pipeline at /company/university-of-virginia).
What development phase is ovarian cancer peptide vaccine in?
ovarian cancer peptide vaccine is in Phase 1.
What are the side effects of ovarian cancer peptide vaccine?
Common side effects of ovarian cancer peptide vaccine include DERMATOLOGY/SKIN:: Injection site reaction/extravasation changes*3, Nausea, Injection site reaction, Fatigue, METABOLIC/LABORATORY:: Albumin, serum-low (hypoalbuminemia)*3, BLOOD/BONE MARROW:: Hemoglobin*3.